10
подписчиков
25
подписок
Не является индивидуальной инвестиционной рекомендацией
Посты
Ролики
GVS
21 декабря 2021
$NVAX
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Novavax on Monday, setting a price target of $294, which is approximately 45.58% above the present share price of $201.95
NV
NVAX
191,07 $
-94,39%
GVS
20 декабря 2021
$NVAX Европейское агентство по лекарственным средствам рекомендовало выдать условное разрешение на продажу вакцины Novavax против COVID-19 (также известной как NVX-CoV2373) для профилактики COVID-19 у людей в возрасте от 18 лет и старше
https://www.ema.europa.eu/en/news/ema-recommends-nuvaxovid-authorisation-eu?s=09
NV
NVAX
201,95 $
-94,69%
GVS
18 декабря 2021
$NVAX
has $15 billion+ sales in 2022 at $16 billion market cap.
BioNTECH market cap is $70 billion.
$NVAX needs to be at $920 to get a market cap of $70 billion.
#ema approval is coming next week
#uk approval is coming in December
#india approval is coming in January
#fda approval is coming in January
#japan approval is coming in January
#korea approval is coming in January
#nvax flu vaccine is coming in July of 2022
NV
NVAX
217,32 $
-95,07%
GVS
16 декабря 2021
$NVAX
- World Health Organization to consider Emergency Use Authorization (EUA) of SII's Covovax today.
- Novavax files for EUA in Japan just now.
NV
NVAX
194,92 $
-94,5%
GVS
15 апреля 2021
$MRNA Researchers at the University of Oxford, the same university that helped develop drug company AstraZeneca’s vaccine, found that the rare blood clotting known as cerebral venous thrombosis occurred in four in a million people receiving the vaccines from drug company Pfizer and biotech Moderna.
MR
MRNA
159,87 $
+23,74%
GVS
23 декабря 2020
MR
MRNA
130,34 $
+51,77%